Zinc alpha 2 glycoprotein as an early biomarker of diabetic nephropathy in patients with type 2 diabetes mellitus

El-Sheikh, Mohamed; Elhefnawy, Khaled A; George, Emad; Ismail, Mabrouk I.; Borai, Maher

doi:10.1590/2175-8239-jbn-2018-0200

Cited by 11 publications

(8 citation statements)

References 29 publications

(36 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Limited cross‐sectional studies have suggested a relationship between plasma ZAG and eGFR in type 2 diabetes [25,26]. Consistently, we showed that higher plasma ZAG tertiles identified people who displayed reduced eGFR levels.…”

Section: Discussionsupporting

confidence: 86%

“…Elevated plasma ZAG levels were observed in HIV-infected adults with nonproteinuric CKD [15]. In type 2 diabetes, non-albuminuric individuals with renal hyperfiltration displayed greater levels of ZAG than those with normal kidney function [16,17]. A proteomics analysis of people with type 2 diabetes showed a trend of higher urinary ZAG levels in non-albuminuric CKD compared with classic CKD [18].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Zinc‐α2‐glycoprotein is associated with non‐albuminuric chronic kidney disease progression in type 2 diabetes: a retrospective study with 4‐year follow‐up

et al. 2020

View full text Add to dashboard Cite

Aim To investigate the association between baseline plasma zinc-a2-glycoprotein and non-albuminuric chronic kidney disease progression in type 2 diabetes. Methods Adults with normoalbuminuria at entry (n=341; age 57AE10 years, 52% men) were analysed. Chronic kidney disease progression was defined as a decrease in chronic kidney disease stage and a decline of ≥25% in estimated GFR from baseline. Baseline plasma zinc-a2-glycoprotein levels were quantified by immunoassay, and analysed either as a continuous variable or by tertiles in Cox proportional hazards models. Model discrimination was assessed using Harrell's C-index. A sensitivity analysis was performed on a subset of individuals who maintained normoalbuminuria during follow-up. Results Chronic kidney disease progression occurred in 54 participants (16%). Zinc-a2-glycoprotein levels were elevated in chronic kidney disease progressors (P = 0.011), and more progressors were assigned to the higher zinc-a2glycoprotein tertile than non-progressors. In the unadjusted Cox model, zinc-a2-glycoprotein, both as a continuous variable (hazard ratio 1.72, 95% CI 1.08-2.75) and tertile 3 (vs tertile 1; hazard ratio 2.14, 95% CI 1.10-4.17), predicted chronic kidney disease progression. The association persisted after multivariable adjustment. The C-index of the Cox model increased significantly after incorporation of zinc-a2-glycoprotein into a base model comprising reninangiotensin system antagonist usage. Sensitivity analysis showed that zinc-a2-glycoprotein independently predicted chronic kidney disease progression among individuals who maintained normoalbuminuria during follow-up. Conclusions Plasma zinc-a2-glycoprotein is associated with chronic kidney disease progression, and may serve as a useful early biomarker for predicting non-albuminuric chronic kidney disease progression in type 2 diabetes.

show abstract

Section: Discussionsupporting

confidence: 86%

Section: Introductionmentioning

confidence: 99%

Zinc‐α2‐glycoprotein is associated with non‐albuminuric chronic kidney disease progression in type 2 diabetes: a retrospective study with 4‐year follow‐up

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Zinc-alpha-2-glycoprotein (ZAZG) is a single-chain polypeptide secreted in various body fluids, such as serum and urine. Despite the fact that functions of ZAZG still remain unknown, some reports suggest that ZAZG has a lot of important functions in the human body, including fertilization and lipid mobilization, therefore it is considered as a multidisciplinary protein [86,87]. As its structural organization and folding characteristics are similar to the MHC class I antigen-presenting molecule, it may have a biological role in the immune response.…”

Section: The Promising Serum and Urinary Proteomic Biomarkers Of Medication-overuse Headachementioning

confidence: 99%

“…As its structural organization and folding characteristics are similar to the MHC class I antigen-presenting molecule, it may have a biological role in the immune response. ZAZG is used as a tumor biomarker for various carcinomas [87]. However, some immunohistochemical analyses have shown predominant expression in the kidney tubules of the human [88].…”

Section: The Promising Serum and Urinary Proteomic Biomarkers Of Medication-overuse Headachementioning

confidence: 99%

Candidate Genes and Proteomic Biomarkers of Serum and Urine in Medication-Overuse Headache

Shnayder

Sharavii

Петрова

et al. 2021

IJMS

View full text Add to dashboard Cite

Chronic headache is a topical problem of neurology, psychiatry and general practice. The medication-overuse headache (MOH) is one of the leading pathologies in the structure of chronic headache. However, early diagnosis of the MOH is challenging. We analyzed potential proteomic biomarkers of serum and urine in patients with MOH. Methods: We searched PubMed, Springer, Scopus, Web of Science, ClinicalKey, and Google Scholar databases for English publications over the past 10 years using keywords and their combinations. Results: We found and analyzed seven studies that met the search criteria for the purpose of the review, including 24 serum proteomic biomarkers and 25 urine proteomic biomarkers of MOH. Moreover, the candidate genes and locus of the studied serum (vitamin D-binding protein, lipocalin-type prostaglandin D2 synthase, apolipoprotein E, etc.) and urine proteomic biomarkers (uromodulin, alpha-1-microglobulin, zinc-alpha-2-glycoprotein, etc.) of MOH are presented in this review. Conclusions: The serum and urine proteomic biomarkers of MOH can potentially help with the identification of patients with MOH development. Due to the relevance of the problem, the authors believe that further investigation of the MOH proteomic biomarkers in different ethnic and racial groups of patients with primary headache is necessary. In addition, it is important to investigate whether medications of different drug classes influence the levels of serum and urine proteomic biomarkers.

show abstract

“…1575 studies were identified, of which 14 (16 cohorts) were included in the present review (publication dates spanning from 2008 to 2019) (13,(26)(27)(28)(29)(30)(31)(32)(33)(34)(35)(36)(37)(38). Further detail of the study selection process can be seen in supplementary materials (Supplementary Materials Section 2: Fig.…”

Section: Systematic Reviewmentioning

confidence: 99%

Zinc-alpha2-glycoprotein, dysglycaemia and insulin resistance: a systematic review and meta-analysis

Pearsey

Henson

Sargeant

et al. 2020

Rev Endocr Metab Disord

View full text Add to dashboard Cite

To systematically review the current literature investigating associations between zinc-alpha2-glycoprotein (ZAG) and dysglycaemia (including type 2 diabetes (T2DM), poly-cystic-ovary syndrome (PCOS), pre-diabetes or insulin resistance). This included relationships between ZAG and continuous measures of insulin and glucose. Additionally, we performed a meta-analysis to estimate the extent that ZAG differs between individuals with or without dysglycaemia; whilst examining the potential influence of adiposity. A systematic search was performed on four databases for studies on circulating ZAG concentrations in adult human populations, comparing healthy controls to individuals with dysglycaemia. Key characteristics, including the mean ZAG concentrations (mg∙L−1), and any correlational statistics between ZAG and continuous measures of glucose, glycated haemoglobin (HbA1c) or insulin were extracted. Meta-analyses were performed to compare metabolically healthy controls to cases, and on studies that compared controls and cases considered overweight or obese (body mass index (BMI) ≥25 kg.m2). 1575 papers were identified and 14 studies (16 cohorts) were considered eligible for inclusion. Circulating ZAG was lower in individuals with dysglycaemia compared to metabolically healthy controls (−4.14 [−8.17, −0.11] mg.L−1; I2 = 98.5%; p < 0.001). When using data from only studies with overweight or obese groups with or without dysglycaemia (three studies (four cohorts); pooled n = 332), the difference in circulating ZAG was no longer significant (−0.30 [−3.67, 3.07] mg. L−1; I2 = 28.0%; p = 0.225). These data suggest that ZAG may be implicated in dysglycaemia, although there was significant heterogeneity across different studies and the mediating effect of adiposity cannot be excluded. Therefore, more research is needed before robust conclusions can be drawn.

show abstract

Zinc alpha 2 glycoprotein as an early biomarker of diabetic nephropathy in patients with type 2 diabetes mellitus

Cited by 11 publications

References 29 publications

Zinc‐α2‐glycoprotein is associated with non‐albuminuric chronic kidney disease progression in type 2 diabetes: a retrospective study with 4‐year follow‐up

Zinc‐α2‐glycoprotein is associated with non‐albuminuric chronic kidney disease progression in type 2 diabetes: a retrospective study with 4‐year follow‐up

Candidate Genes and Proteomic Biomarkers of Serum and Urine in Medication-Overuse Headache

Zinc-alpha2-glycoprotein, dysglycaemia and insulin resistance: a systematic review and meta-analysis

Contact Info

Product

Resources

About